Interestingly, Neri et al. recently reported that elevated PARP1 expression was correlated with poor survival in MM and bortezomib-induced “BRCAness” (tumor cells with the homologous recombination deficiency) showed synergistic anti-tumor effects when paired with PARP1 inhibitors for killing MM cells [7]. This evidence concerns the gene PARP1 and Miyoshi myopathy.